Second-Line Therapy Options
A panelist discusses how second-line treatment options for kidney cancer have evolved through multiple clinical trials including Study 205, METEOR, CONTACT-03, TIVO-3, TiNivo-2, and LITESPARK-005, which have demonstrated varying efficacy across different patient populations and prior therapies, particularly noting the impact of prior immunotherapy exposure on treatment selection and the need for careful consideration of historical trial data in the context of modern treatment paradigms.
Video content above is prompted by the following:
- What are the second-line options for this patient per the NCCN guidelines for kidney cancer?
- Please provide a brief overview of the efficacy and safety data supporting these options, as appropriate (eg, phase 2 Study 205, METEOR, control arm of CONTACT-03, TIVO-3, control arm of TiNivo-2, LITESPARK-005)
- How do the populations of these trials compare? Distinctions in approved indications (eg, line of therapy; prior ICI).
- What are the trends that have emerged with long-term follow up?
- What guidance can you offer community oncologists when critically weighing the evidence from studies of the second-line options?
- What are the limitations of applying data from older studies in modern practice (eg, prior ICI)?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
